CLEC1B and neoplasm: P-selectin (128), CLEC-2 (129), protease-activated receptor 1 (PAR-1) (130), and integrins (including αIIbβ3, αvβ3, α6β1, and α2β1) (131) can all serve as key receptors that mediate the binding and activation of platelets and tumor cells, plays a role in tumor progression and has the potential to serve as an anti-cancer target.